|
Pulmonary Edema
|
0.200 |
Biomarker
|
phenotype |
RGD |
This work provides further insight into the relationship between mob-1 and TNF-alpha in the development of lung injury assessed by pulmonary edema and leukosequestration.
|
12353928 |
2002 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome and epigenome wide studies of neurological protein biomarkers in the Lothian Birth Cohort 1936.
|
31320639 |
2019 |
|
mathematical ability
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals.
|
30038396 |
2018 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Evaluating SMS1 expression level in tumor samples might serve as a biomarker to predict clinical outcome in advanced melanoma patients.
|
31114500 |
2019 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
By studying these variants in human cancer cells and Drosophila, we uncovered that MOB1/Warts binding is essential for tumor suppression, tissue growth control, and development, while stable MOB1/Hippo binding is dispensable and MOB1/Trc binding alone is insufficient.
|
28947795 |
2017 |
|
Multiple Chronic Conditions
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
These circRNAs consist mainly of portions of the multi-exon 5' untranslated region (5'UTR) of the SGMS1 gene and include one to five exons.
|
27449796 |
2017 |
|
Multiple Chronic Conditions
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Here the authors employ a multi-disciplinary approach to characterize the interactions of the three Hippo kinases with the signaling adaptor MOB1 and show how they differently affect development, tissue growth and tumor suppression.
|
28947795 |
2017 |
|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Knockdown of SMS1 attenuates AD-like pathology through promoting lysosomal degradation of BACE1.
|
30243987 |
2019 |
|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Sphingomyelin synthase 1 (SMS1) has been reported to participate in hepatitis and atherosclerosis.
|
31262710 |
2019 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Sphingomyelin synthase 1 (SMS1) has been reported to participate in hepatitis and atherosclerosis.
|
31262710 |
2019 |
|
Autoimmune Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
These data suggest that SMS1 is involved in lupus-like autoimmunity via regulating BCR signal transduction and B cell activation.(Word count for the abstract: 230).
|
31262710 |
2019 |
|
Encephalitis, St. Louis
|
0.010 |
Biomarker
|
disease |
BEFREE |
SMS1 knockout lupus-like animal model and SLE patient samples were utilized.
|
31262710 |
2019 |
|
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>Conclusions</i>: SMS1 and SMS2 showed opposite associations with glioma patient survival, glioma cell growth and response to 2OHOA treatment.
|
30646599 |
2019 |
|
Hepatitis
|
0.010 |
Biomarker
|
group |
BEFREE |
Sphingomyelin synthase 1 (SMS1) has been reported to participate in hepatitis and atherosclerosis.
|
31262710 |
2019 |
|
Hepatitis A
|
0.010 |
Biomarker
|
disease |
BEFREE |
Sphingomyelin synthase 1 (SMS1) has been reported to participate in hepatitis and atherosclerosis.
|
31262710 |
2019 |
|
Lupus Vulgaris
|
0.010 |
Biomarker
|
disease |
BEFREE |
SMS1 deficiency also displayed lower autoantibody titers and 24 h urine protein excretion in bm12-induced lupus, which were associated with reduced B-cell activation.
|
31262710 |
2019 |
|
Lupus Erythematosus, Discoid
|
0.010 |
Biomarker
|
disease |
BEFREE |
SMS1 deficiency also displayed lower autoantibody titers and 24 h urine protein excretion in bm12-induced lupus, which were associated with reduced B-cell activation.
|
31262710 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.010 |
Biomarker
|
disease |
BEFREE |
SMS1 knockout lupus-like animal model and SLE patient samples were utilized.
|
31262710 |
2019 |
|
melanoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Collectively, our study indicates that SMS1 downregulation in melanoma enhances GlcCer synthesis, triggering an imbalance in the SM/GlcCer homeostasis, which likely contributes to melanoma progression.
|
31114500 |
2019 |
|
Renal fibrosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, Kindlin-2 levels are negatively correlated with MOB1 and phosphorylated (p) YAP in samples from patients with renal fibrosis.
|
31825843 |
2019 |
|
Lupus Erythematosus
|
0.010 |
Biomarker
|
disease |
BEFREE |
SMS1 deficiency also displayed lower autoantibody titers and 24 h urine protein excretion in bm12-induced lupus, which were associated with reduced B-cell activation.
|
31262710 |
2019 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Overall, the present results suggested that SMS1 could inhibit EMT and the migration and invasion of MDA‑MB‑231 cells via TGF‑β/Smad signaling pathway.
|
30535436 |
2019 |
|
Glioblastoma Multiforme
|
0.010 |
Biomarker
|
disease |
BEFREE |
SMS1 and SMS2 also had opposing effect on GBM cell survival and 2OHOA's IC<sub>50</sub> correlated with basal SMS1 levels and treatment induced changes in SMS1/SMS2 ratio.
|
30646599 |
2019 |